Carbonic Anhydrase
Carbonate dehydratase
Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.
The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.
Carbonic Anhydrase Isoform Specific Products
-
Carbonic Anhydrase
(192)
View all products
-
CA
(7)
View all products
-
CA I
(67)
View all products
-
CA Ⅱ
(119)
View all products
-
CA IX
(106)
View all products
-
CA XII
(64)
View all products
-
CA VII
(1)
View all products
-
CA VI
(2)
View all products
-
CA VA
(2)
View all products
-
CA VB
(2)
View all products
-
CA XIII
(2)
View all products
-
CA XIV
(2)
View all products
All Product Categories
-
Carbonic Anhydrase Inhibitors
(341)
View all products
-
Carbonic Anhydrase Activators
(3)
View all products
-
Carbonic Anhydrase Modulators
(3)
View all products
-
Carbonic Anhydrase Degrader
(1)
View all products
-
Carbonic Anhydrase Ligands
(3)
View all products
-
Carbonic Anhydrase Proteins
(33)
View all products
-
Carbonic Anhydrase 1 (CA1) Proteins
(1)
View all products
-
Carbonic Anhydrase 2 (CA-II) Proteins
(3)
View all products
-
Carbonic Anhydrase 4 (CA IV) Proteins
(3)
View all products
-
Carbonic Anhydrase 12 (CA-XII) Proteins
(1)
View all products
-
Carbonic Anhydrase Related Products (377)
Related Products (377)
-
Recombinant Proteins (33)
-
Carbonic Anhydrase Isoform Comparison
-
COX-2/CA II-1
0 ImagesCat. No.: HY-184937COX-2/CA II-1 is an orally active dual selective inhibitor targeting COX-2 and hCA II. COX-2/CA II-1 inhibits COX-2 with an IC50 value of 0.13 μM (SI = 9.25 vs COX-1) and hCA II with a Ki value of 39.1 nM (SI = 933.8 vs hCA I). COX-2/CA II-1 demonstrates significant analgesic and anti-inflammatory effects in animal models, shows improved gastric safety with reduced ulcerogenic liability, and exhibits intraocular pressure (IOP)-lowering effects in rabbit glaucoma models. COX-2/CA II-1 can be used for anti-inflammatory, analgesic and antiglaucoma research.
-
DTP348
0 ImagesCat. No.: HY-120367CAS No.: 1383370-92-0DTP348 is an inhibitor for carbonic anhydrase IX with a Ki of 8.3 nM in vitro and an IC50 of 19.26 μM in Xenopus oocytes. DTP348 exhibits slight toxicity in zebrafish embryos with LD50 of 3.5 mM. DTP348 can be used in the anti-cancer research.
-
Carbonic anhydrase activator 1
0 ImagesCat. No.: HY-175441CAS No.: 2374923-30-3Carbonic anhydrase activator 1 (Compound 17) is an orally active and a BBB-penetrable Carbonic anhydrase (CA) activator with KAs of 7.8, 3.9 and 2.1 μM for hCA I, hCA VA and hCA VII. Carbonic anhydrase activator 1 can be used for cancers, glaucoma, cardiovascular diseases and neurodegenerative disorders like epilepsy research.
-
Elsulfavirine sodium
0 ImagesCat. No.: HY-109056ACAS No.: 867365-40-0Synonyms: R-1206 sodiumElsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.
-
hCAXII-IN-3
0 ImagesCat. No.: HY-147984CAS No.: 2417232-24-5hCAXII-IN-3 (Compound 6o) is a selective human carbonic anhydrase XII (hCAXII) inhibitor with a Ki of 10.0 nM.
-
CAII-IN-2
0 ImagesCat. No.: HY-151494CAII-IN-2 (compound 3g), a thiosemicarbazide derivative, is a potent, selective carbonic anhydrase-II (CA-II) inhibitor with an IC50 value of 12.1 µM for bovine CA-II. CAII-IN-2 can be used in research of carbonic anhydrase related biological disorders.
-
NSC 828467
0 ImagesCat. No.: HY-144222CAS No.: 3033384-72-1NSC 828467 exhibited significant in vitro anticancer activity,and it is one of the top-five CA IX inhibitors with an IC50 value of 27.2nM.
-
DOTA-XYIMSR-01
0 ImagesCat. No.: HY-173116CAS No.: 2051527-54-7DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy.
-
Brinzolamide-d5 hydrochloride
0 ImagesCat. No.: HY-B0588ASSynonyms: AL-4862-d5 hydrochlorideBrinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride. Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research.
-
L-693612 hydrochloride
0 ImagesCat. No.: HY-19213ACAS No.: 138301-72-1L-693612 hydrochloride (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
-
Carbonic anhydrase inhibitor 33
0 ImagesCat. No.: HY-172899Carbonic anhydrase inhibitor 33 (11D) is a dual inhibitor of CA (Carbonic anhydrase) IX/XII and CDK6, with Ki values of 19.7 nM and 26.1 nM for hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 33 (11D) induces G1 arrest and apoptosis. Carbonic anhydrase inhibitor 33 (11D) can be used in the research for NSCLC.
-
CA
IX-IN-6
0 ImagesCat. No.: HY-187174CA IX-IN-6 is a selective human carbonic anhydrase IX (hCA IX) inhibitor, with Ki values of 8.9, 50.7, 551, and 64.4 nM against hCA IX, hCA XII, hCA I, and hCA II, respectively. CA IX-IN-6 binds to the active site via a classic sulfamide mode, coordinates with the catalytic Zn2+ ion, forms a hydrogen bond with Thr200, and interacts with key active site residues. CA IX-IN-6 can be used in studies related to tumor-associated carbonic anhydrase inhibition.
-
hCA XII/II/IX-IN-1
0 ImagesCat. No.: HY-147799hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity.
-
hCA VB-IN-1
0 ImagesCat. No.: HY-147956hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a KI of 515.7 nM.
-
HCAIX-IN-2
0 ImagesCat. No.: HY-146207CAS No.: 2389034-45-9HCAIX-IN-2 (compound 9d) is a selective carbonic anhydrase inhibitor with the Ki values of 24.6 nM and 45.3 nM for hCA IX and hCA XII, respectively.
-
hCAII-IN-7
0 ImagesCat. No.: HY-144268hCAII-IN-7 (Compound R-13) is a potent human carbonic anhydrase (hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively.
-
hA2A/hCA XII modulator 1
0 ImagesCat. No.: HY-146979CAS No.: 2548963-55-7hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research.
-
CDK2-IN-11
0 ImagesCat. No.: HY-150572CAS No.: 2410402-82-1CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer.
-
O-Desmethyl Brinzolamide hydrochloride
0 ImagesCat. No.: HY-W424792ACAS No.: 2967475-56-3O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonic anhydrase (CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV.
